AstraZeneca Blames Germany’s Tender System For Influenza Vaccine Shortages
This article was originally published in The Pink Sheet Daily
AstraZeneca says that shortages of influenza vaccines in Germany are a direct result of the tendering process there, which has blocked the firm’s Fluenz nasal spray product from being prescribed in several federal states.
You may also be interested in...
Government argues that shortages can be avoided by contracting with multiple manufacturers, but industry says changes do not go far enough, and is asking for sales assurances.
GSK believes detrimental government policies such as reference pricing and tendering in the vaccines sector are threatening this part of the pharmaceutical industry, and patient health.
Germany will have its first list of non-substitutable pharmaceuticals since the introduction of discount contracts, but the benefit it offers to original product manufacturers will be severely limited.